Holen Sie sich die Stockscreener-App
17.55
0.80%
0.14
Handel nachbörslich:
17.55
Schlusskurs vom Vortag:
$17.41
Offen:
$17.465
24-Stunden-Volumen:
1.04M
Relative Volume:
0.50
Marktkapitalisierung:
$2.90B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-446.21M
KGV:
-4.9529
EPS:
-3.5434
Netto-Cashflow:
$-423.92M
1W Leistung:
-7.14%
1M Leistung:
-3.20%
6M Leistung:
-22.28%
1J Leistung:
+48.85%
1-Tages-Spanne:
$17.29
$17.91
1-Wochen-Bereich:
$17.29
$19.48
52-Wochen-Spanne:
$8.06
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Firmenname
Dyne Therapeutics Inc
Sektor
Branche
Telefon
(781) 786-8230
Adresse
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
17.55 | 3.00B | 0 | -446.21M | -423.92M | -3.5434 |
VRTX
Vertex Pharmaceuticals Inc
|
427.38 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
707.06 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
781.72 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.49 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
295.27 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-10-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-25 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Bestätigt | Chardan Capital Markets | Buy |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-27 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Eingeleitet | Oppenheimer | Outperform |
| 2023-01-26 | Eingeleitet | Guggenheim | Buy |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Outperform |
| 2020-10-12 | Eingeleitet | JP Morgan | Overweight |
| 2020-10-12 | Eingeleitet | Jefferies | Buy |
| 2020-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Dyne therapeutics director Jason Rhodes sells $4.18m in stock - Investing.com
Atlas Venture funds tied to Dyne (DYN) director sell 227,337 shares - Stock Titan
MSN Money - MSN
Could Dyne Therapeutics (DYN) Turn Its FORCE Platform Into a Broader Neurology Franchise? - simplywall.st
Dyne Therapeutics earnings up next: DMD launch path in focus By Investing.com - Investing.com India
Dyne Therapeutics earnings up next: DMD launch path in focus - Investing.com
Facioscapulohumeral Muscular Dystrophy Market: Pharma Pipeline Fuels Rapid Expansion – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart
Facioscapulohumeral Muscular Dystrophy Market: Pharma - openPR.com
DYN SEC FilingsDyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Director at Dyne Therapeutics (DYN) makes bona fide gift of 53,625 shares - Stock Titan
Dyne Therapeutics Insider Sold Shares Worth $7,101,120, According to a Recent SEC Filing - marketscreener.com
Dyne therapeutics director Jason Rhodes sells $7.1m in stock By Investing.com - Investing.com South Africa
Dyne Therapeutics(DYN.US) Director Sells US$7.1 Million in Common Stock - Moomoo
Dyne therapeutics director Jason Rhodes sells $7.1m in stock - Investing.com
[Form 4] Dyne Therapeutics, Inc. Insider Trading Activity - Stock Titan
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting - The Manila Times
[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
Dyne Therapeutics Announces Upcoming Presentation - GlobeNewswire
Dyne Therapeutics (DYN) Stifel 2026 Virtual CNS Forum Summary - Quartr
Dyne Therapeutics (DYN) Proxy filing Summary - Quartr
Dyne Therapeutics (DYN) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Dyne Therapeutics director Kersten sells $219k in company stock - Investing.com
Dyne Therapeutics director Kersten sells $219k in company stock By Investing.com - Investing.com India
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
[ARS] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
Director-affiliated fund trims Dyne Therapeutics (DYN) stake in 10b5-1 sales - Stock Titan
Dyne Therapeutics (NASDAQ: DYN) sets 2026 virtual meeting, share increase vote - Stock Titan
Dyne used stock awards to hire 18 employees, covering 423,000 shares - Stock Titan
Jason Rhodes Sells 274,297 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 272,049 Shares of Stock - MarketBeat
Dyne therapeutics director Jason Rhodes sells $16.48m in shares By Investing.com - Investing.com South Africa
Dyne Therapeutics(DYN.US) Director Sells US$16.48 Million in Common Stock - Moomoo
Atlas Venture funds sell Dyne (DYN) shares under 10b5-1 plan - Stock Titan
Dyne therapeutics director Dirk Kersten sells $6.8m in shares By Investing.com - Investing.com Australia
Dyne therapeutics director Dirk Kersten sells $6.8m in shares - Investing.com UK
DYN (Nasdaq) Form 144: Atlas Venture groups report proposed sales totaling tens of thousands of shares - Stock Titan
Atlas Venture affiliates sell shares of DYN (Nasdaq: DYN) in Rule 144 notices - Stock Titan
Atlas Venture sells DYN stock (Nasdaq: DYN) — 142,571-share entry listed - Stock Titan
Atlas Venture entities sell DYN shares (NASDAQ: DYN) under Form 144 disclosure - Stock Titan
Director-linked fund trims 337K Dyne Therapeutics (DYN) shares under 10b5-1 plan - Stock Titan
H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Dyne Therapeutics: De-Risked DMD Opportunity, Pivotal DM1 Readout, and Emerging M&A Appeal Support Buy Rating - TipRanks
H.C. Wainwright reiterates Dyne Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Finanzdaten der Dyne Therapeutics Inc-Aktie (DYN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):